Literature DB >> 23426706

Lipid accumulation product is related to metabolic syndrome in women with polycystic ovary syndrome.

S Xiang1, F Hua, L Chen, Y Tang, X Jiang, Z Liu.   

Abstract

PURPOSE: Metabolic disturbances are common features of polycystic ovary syndrome (PCOS), which possibly enhance the risk of diabetes and cardiovascular disease. Lipid accumulation product (LAP) is an emerging cardiovascular risk factor. The aim of this study was to explore the ability of LAP to identify metabolic syndrome (MS) in PCOS women.
METHODS: In a cross-sectional study, anthropometric, biochemical and clinical parameters were measured in 105 PCOS women. Receiver operating characteristic (ROC) analysis was used to find out the cut-off points of LAP to predict MS. MS was categorized according to International Diabetes Federation (IDF) criteria.
RESULTS: The prevalence of MS was 43.8% in this study. PCOS women with MS had significantly higher LAP levels compared to those without MS. LAP was highly correlated with components of MS. ROC analysis showed that LAP was a significant discriminator for MS in PCOS women, and the optimal cutoff point of LAP to predict MS was 54.2 (93.3% sensitivity, 96.7% specificity).
CONCLUSIONS: LAP seems to be associated with MS and has a strong and reliable diagnostic accuracy for MS in PCOS women. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23426706     DOI: 10.1055/s-0032-1333261

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  13 in total

1.  Lipid accumulation product and metabolic syndrome: a population-based study in northern Iran, Amol.

Authors:  N Motamed; S Razmjou; G Hemmasi; M Maadi; F Zamani
Journal:  J Endocrinol Invest       Date:  2015-08-29       Impact factor: 4.256

2.  Association of IL-1β, IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome.

Authors:  Nadia Rashid; Aruna Nigam; Pikee Saxena; S K Jain; Saima Wajid
Journal:  Inflamm Res       Date:  2017-04-12       Impact factor: 4.575

3.  Lipid accumulation product is associated with insulin resistance, lipid peroxidation, and systemic inflammation in type 2 diabetic patients.

Authors:  Parvin Mirmiran; Zahra Bahadoran; Fereidoun Azizi
Journal:  Endocrinol Metab (Seoul)       Date:  2014-05-27

4.  Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults.

Authors:  Haijiang Dai; Weijun Wang; Ruifang Chen; Zhiheng Chen; Yao Lu; Hong Yuan
Journal:  Nutr Metab (Lond)       Date:  2017-08-01       Impact factor: 4.169

5.  Visceral adiposity index, lipid accumulation product and intracranial atherosclerotic stenosis in middle-aged and elderly Chinese.

Authors:  Rui Li; Qi Li; Min Cui; Zegang Ying; Lin Li; Tingting Zhong; Yingchao Huo; Peng Xie
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

6.  Clinical surrogate markers for predicting metabolic syndrome in middle-aged and elderly Chinese.

Authors:  Rui Li; Qi Li; Min Cui; Zegang Yin; Ling Li; Tingting Zhong; Yingchao Huo; Peng Xie
Journal:  J Diabetes Investig       Date:  2017-08-03       Impact factor: 4.232

7.  Women with Polycystic Ovary Syndrome and Risk of Cardiovascular Disease.

Authors:  Iva Perovic Blagojevic; Tatjana Eror; Jovana Pelivanovic; Svetlana Jelic; Jelena Kotur-Stevuljevic; Svetlana Ignjatovic
Journal:  J Med Biochem       Date:  2017-07-14       Impact factor: 3.402

8.  Usefulness Of Surrogate Markers Of Body Fat Distribution For Predicting Metabolic Syndrome In Middle-Aged And Older Korean Populations.

Authors:  Kyung-A Shin; Young-Joo Kim
Journal:  Diabetes Metab Syndr Obes       Date:  2019-11-01       Impact factor: 3.168

9.  Lipid accumulation product is a predictor of nonalcoholic fatty liver disease in childhood obesity.

Authors:  Bahar Özcabı; Salih Demirhan; Mesut Akyol; Hatice Öztürkmen Akay; Ayla Güven
Journal:  Korean J Pediatr       Date:  2019-10-28

10.  Three novel obese indicators perform better in monitoring management of metabolic syndrome in type 2 diabetes.

Authors:  Chun-Ming Ma; Na Lu; Rui Wang; Xiao-Li Liu; Qiang Lu; Fu-Zai Yin
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.